(S042) Phase I–III Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience Over 30 Years

OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

We present demographics and factors associated with slow trial accrual at MDACC. We believe that this analysis serves as a baseline and highlights areas of weakness to aid in the development of evidence-based trial guidelines.

Chad Tang, MD, Steven I. Sherman, MD, Mellanie Price, Jun Weng, Suzanne Davis, MBA, MMS, David Hong, MD, Aman Buzdar, MD, J. J. Lee, PhD, MS, DDS; UT MD Anderson Cancer Center

PURPOSE: Increasingly limited resources mandate the careful allocation of assets for cancer research. Slow-accruing clinical trials delay the translation of biomedical research, contribute to increasing healthcare costs, and often languish unfinished. We analyzed The University of Texas MD Anderson Cancer Center (MDACC) experience for factors that predict slow participant accrual to phase I–III trials.

MATERIALS AND METHODS: Clinical Oncology Research system (CORe) is a prospectively maintained institutional database that tracks all clinical studies at MDACC. We evaluated studies that met the following inclusion criteria: activated phase I–III trials, maximum projected accrual ≥ 10 participants, and activation prior to March 2011. The primary outcome was slow accrual, defined as an accrual rate of < 2 participants per year. Correlations of trial characteristics and development variables with slow accrual were assessed with univariate and multivariate logistic regression. Additional slow accrual cutpoints and a Bonferroni-adjusted significance threshold of P < .003 were utilized to ensure robust associations.

RESULTS: A total of 4,269 clinical trials met the inclusion criteria. Trials were activated between 1981 and 2011, with 145,214 participants enrolled. Median total enrollment was 17 (interquartile range [IQR]: 6–38), with an average rate of 8.7 participants/year (IQR: 3.3–17.7). There were 755 (18%) trials classified as slow-accruing.

On multivariate analysis, slow accrual exhibited robust associations with national cooperative group trials (odds ratio [OR], 4.16; P < .0001 vs industry-sponsored) and time from trial activation to first enrollment (OR, 1.13 per month; P < .0001). Factors that were not robustly associated with slow accrual included the number of concurrent trials activated within the same department, year of trial activation, and trial phase. Slow-accruing trials led to a lower rate of peer-reviewed publication (14%) than non–slow-accruing trials (69%).

CONCLUSIONS: We present demographics and factors associated with slow trial accrual at MDACC. We believe that this analysis serves as a baseline and highlights areas of weakness to aid in the development of evidence-based trial guidelines.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.